Introduction
T hyroid follicular cells have the ability to concentrate iodide in order to produce thyroid hormones. Excessive iodine levels in the serum exert an autoregulatory influence on the thyroid gland, blocking cell proliferation and thyroid function (1, 2) . These effects have been partially at-thyroid follicular cells, blocking ERK phosphorylation and delaying loss of thyroid differentiation markers (8) .
In silico analyses have revealed that the TGFb signaling pathway is targeted by the miR-17-92 cluster (9) , which is comprised of seven microRNAs (miRNA): miR-17 (5p and 3p strands), miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1. This cluster of genes is frequently deregulated in cancers, including thyroid cancer (10) (11) (12) (13) . miRNAs are small noncoding RNAs (*22 nucleotides) that negatively regulate translation of target mRNAs and have emerged as important modulators of the oncogenic process (14) .
The BRAF 1799T > A mutation, resulting in the BRAF V600E oncoprotein, is highly prevalent in papillary thyroid cancer (PTC), the most common histotype of thyroid cancer. This alteration is also observed in anaplastic thyroid cancers (ATC) derived from PTCs (15, 16) . Expression of the BRAF V600E oncoprotein deregulates a plethora of signaling pathways to promote thyroid cancer. One such pathway is the Notch pathway, which is activated by the BRAF V600E oncoprotein in thyroid follicular cells and is upregulated in human PTC (17) . Interestingly, deregulation of the Notch signaling pathway in cancer is not only associated with tumor initiation, but also tumor progression via epithelial to mesenchymal transition (18) .
In this study, we show that BRAF V600E activates miR-17-92 via upregulation of Notch signaling. We also demonstrate that miR-19 targets Smad4 in thyroid follicular cells. Moreover, high iodine reduces the oncogenic effects of BRAF V600E by blocking Notch signaling activation and miR-19 upregulation, restoring TGFb inhibitory signaling. Thus, we report a new protective role for iodine in cells undergoing BRAF activation.
Materials and Methods

Cell lines
PC-BRAF V600E -6 cells, derived from PCCl3 rat thyroid follicular cells (19) , conditionally express BRAF V600E under doxycycline treatment. These cells were cultivated in F-12 Coon's Modification medium (Sigma, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS), 1 mU/mL bovine thyrotropin (TSH; Sigma), 10 lg/mL insulin (Sigma), 5 lg/mL transferrin (Sigma), 10 nM hydrocortisone (Sigma), 300 lg/mL neomycin (Invitrogen, Carlsbad, CA), and 100 lg/mL hygromycin (Invitrogen). PC-Notch1 cells (17) , also derived from PCCl3 cells, constitutively express the Notch intracellular domain and were cultivated in the same medium described above, but in the absence of hygromycin.
Nthy-ori 3-1 cells (Sigma), derived from human normal thyroid follicular cells immortalized with the SV40 virus, were cultivated in RPMI (Invitrogen) supplemented with 10% FBS and 2 mM l-glutamine (Invitrogen 
Cell treatments
Sodium iodide and doxycycline. High concentration iodine treatment was performed by diluting a 1 M stock solution of sodium iodide (NaI) in the medium to a final concentration of 10 lM NaI. PC-BRAF V600E -6 cells were treated with 10 lM iodine for five days. BRAF V600E activation was performed by adding 1 lg/mL doxycycline (Calbiochem, San Diego, CA) to the culture medium for 48 hours. PC-BRAF V600E -6 cell groups were described as follows. The Control group includes cells without any treatment; the BRAF group includes cells in which BRAF 1799T > A was induced by doxycycline treatment; the Iodine group contains cells treated with 10 lM NaI; and the BRAF/Iodine group contains cells treated with both doxycycline and NaI.
Recombinant TGFb1. PC-BRAF V600E -6 and BCPAP cells were treated for 24 hours with exogenous recombinant TGFb (rTGFB; Peprotech, Rocky Hill, NJ) in the culture medium at doses of 1 ng/mL and 10 ng/mL respectively. miR-19 mimics and anti-miR. miR-19 modulation was performed using the mirVanaÔ miRNA mimic (Ambion, Austin, TX), which overexpresses hsa-miR-19a-3p and hsamiR-19b-3p, or the mirVanaÔ miRNA inhibitor (Ambion) containing LNA modification, which inhibits hsa-miR-19a-3p and hsa-miR-19b-3p (anti-miRs). All transfections were performed using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's instructions.
Notch1 siRNA (small interfering RNA). Notch1 knockdown in PC-BRAF V600E -6 and KTC2 cells was performed by transient transfection (48 hours) of 10 nM or 60 nM NOTCH1 siRNA (esiRNA human NOTCH1-EHU150431; Sigma) respectively. Control cells were transfected with an EGFP siRNA (EGFP-EHUGFP; Sigma). All transfections were performed using LipofectamineÔ 2000 according to the manufacturer's instructions. Validation of decreased NOTCH1 expression was performed as previously described (17) .
Analysis of microRNA expression RNA extraction. Small RNA (sRNA) was isolated using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. sRNA integrity was analyzed using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) in combination with the Agilent Small RNA kit.
Mature miRNA levels. Briefly, 10 ng of sRNA was reverse transcribed using the TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA) in the presence of stem-loop primers. Quantitative PCR was then performed, using the TaqMan Ò MicroRNA Assays for miR-17-5p (assay 393), miR-18a-5p (assay 2422), miR-19a-3p (assay 395), miR-19b-3p (assay 396), miR-20a-5p (assay 580), miR-92a-3p (assay 430), miR-146b-5p (assay 1097), snoRNA (small nucleolar RNA) (assay 1718), or RNU6B (U6B nuclear RNA; assay 1093; Applied Biosystems); TaqMan Ò Universal PCR Master Mix; and No AmpErase Ò UNG (Life Technologies) in a ABI Ò 7300 Sequence Detection System (PE Applied Biosystems). Gene expression was normalized by comparison to snoRNA or RNU6B levels and calculated using the QGene program (20) .
Western blot analyses
Total protein was extracted from cell lines using RIPA buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycholate; 1 mM EDTA; and 0.1% SDS) containing 10% protease inhibitor cocktail (Sigma). Protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA), and 40 lg of each sample was resolved on a 10% acrylamide gel by SDS-PAGE and blotted to a Hybond-ECL nitrocellulose membrane (Amersham Biosciences, Little Chalfont, United Kingdom). Nonspecific binding sites were blocked using 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween-20. The following primary antibodies were used: rabbit anti-SMAD4 (sc-7866), rabbit anti-NOTCH1 (sc-6014), mouse anti-a-tubulin (sc-5286), and mouse anti-b-actin (sc-47778; Santa Cruz, Santa Cruz, CA). The rabbit anti-Nis antibody was kindly donated by Dr. Sissy Jhang. The antigen-antibody complexes were detected with corresponding horseradish peroxidase-conjugated secondary antibodies. Chemiluminescence emission was visualized with luminol and p-cumaric acid (Sigma) in the presence of H 2 O 2 using an ImageQuant LAS4000 imaging system (GE Healthcare, Little Chalfont, United Kingdom).
Luciferase assay miR-19 target validation. A segment of the rat Smad4 3¢-untranslated region (UTR) containing the predicted binding site for miR-19a/miR-19b (position 1297-1303) based on TargetScan database (www.targetscan.org) was cloned into the pmiR-Glo plasmid (pmiR-Glo-Smad4-wt plasmid; Promega, Madison, WI) according to the manufacturer's instructions. A second version of the Smad4 3¢-UTR containing a mutated binding site was also cloned into the same vector (pmiR-Glo-Smad4-mut; Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/ thy). N-thy ori-3.1cells were transiently transfected with pmiR-Glo-Smad4-wt or pmiR-Glo-Smad4-mut in the presence of 10 nM miR-19a/ miR-19b mimics and/or 10 nM antimiR-19a/miR-19b antisense oligonucleotides. In order to evaluate miR-19 site specificity, we also overexpressed let-7a via the pH1-RNA-puro-let7a plasmid. Forty-eight hours after transfection, the cell lysate was collected, and firefly luciferase activity was measured in a SpectraMax L luminometer (Molecular Devices, Sunnyvale, CA) using the Dual Luciferase Ò Reporter Assay System (Promega).
Notch signaling activation. Activation of Notch signaling results in cleavage of the Notch receptor and release of the Notch intracellular domain (NICD), which translocates into the nucleus and interacts with specific factors, such as CBF1, to bind and regulate target gene expression. In order to evaluate Notch signaling activation, we used the reporter plasmid 4xwtCBF1Luc, which contains four CBF1 binding sites, and 4xmutCBF1Luc, which contains mutated binding sites and served as a control (21) . PC-BRAF V600E -6 cells were transfected with 4xwtCBF1Luc or 4xmutCBF1Luc and pRL plasmid, and lysate was collected 48 hours after transfection. Luminescence was measured as described above. FUZIWARA AND KIMURA
TGFb responsiveness
Cells were detached by trypsinization and fixed with 70% ethanol. After hydration in PBS, cells were treated with RNase (100 lg/mL). The cell cycle was evaluated by analyzing DNA content of cells stained with propidium iodide (50 lg/mL) by flow cytometry (10,000 events, red emission) using Guava EasyCyte Mini (Guava Technologies, Hayward, CA).
Bioinformatics miR-19a and miR-19b target prediction analysis was performed using the TargetScan database (22) . The rat and human miR-17-92 promoter regions (5 kb upstream) were analyzed for potential transcription factor binding sites using Transcription Element Search System (TESS) software available online (23) .
Statistical analyses
Results are presented as the mean -standard deviation (SD). Significant differences were assessed by analysis of variance followed by the Tukey test to compare more than two groups or the t-test to compare two groups. p-Values of <0.05 were considered significant.
Results
High iodine blocks BRAF V600E -induced miR-17-92 expression
In this study, we assessed the effects of iodine treatment on miRNA expression during acute BRAF V600E oncogene activation in thyroid follicular cells (Fig. 1) . We observed that induction of BRAF V600E expression in PC-BRAF V600E -6 cells by doxycycline strongly increased the levels of each of the components of the miR-17-92 cluster after 48 hours of treatment (Fig. 1) . miRNAs belonging to the miR-17-92 cluster were differentially induced by expression of the BRAF oncogene, as miR-17-5p, miR-18a, miR-19a, miR-19b, miR20a, and miR-92a exhibited approximately 45, 62, 630, 142, 7, and 2-fold increase, respectively, relative to the control group. In contrast, treatment of PC-BRAF V600E -6 cells with high iodine prior to BRAF induction (BRAF/Iodine group) blocked the increase of miR-17-5p, miR-18a, and miR19b, partially blocked that of miR-19a and miR-20a, but had no effect on miR-92a expression. Interestingly, treatment with high iodine alone (Iodine group) induced expression of miR-20a and miR-92a (Fig. 1) . We also assessed levels of miR-146b, a hallmark miRNA for PTC, and observed that expression of BRAF increased miR-146b expression, but iodine treatment did not reverse this induction (Fig. 1) .
High iodine blocks BRAF-induced activation of Notch signaling
In order to determine whether the miR-17-92 gene underwent transcriptional regulation in response to BRAF expression, we investigated its putative promoter region for predicted transcription factor binding sites. In silico analysis of 5 kb of sequence upstream of the rat miR-17-92 gene using the TESS tool (23) revealed several potential transcription factor binding sites in this region, including five putative binding sites for Hes1, a downstream target of Notch signaling. In the sequence 5 kb upstream the human miR-17-92 gene, we found two putative HES1 binding sites. Moreover, recently, it was shown that Notch1 is activated in human PTC and that BRAF V600E induction stimulates Notch signaling in thyroid follicular cells (17) .
Therefore, we next analyzed expression of Notch1, the transmembrane receptor for Notch signaling, and observed that iodine treatment reduced Notch1 protein levels during BRAF induction (Fig. 2A) . In order to analyze Notch signaling activity during high iodine treatment of BRAFinduced cells (BRAF/Iodine group), we transfected cells with a reporter plasmid containing four CBF binding sites (4xCBF1Luc). We observed that iodine treatment blocked BRAF-mediated activation of Notch signaling (Fig. 2B) .
Notch signaling influences miR-19 expression
By transfecting cells with targeted small interfering RNAs (siRNAs), we observed that the knockdown of Notch1 in Fig. 3A ) resulted in decreased expression of miR-19a and miR-19b (Fig.  3B) . Moreover, knockdown of NOTCH1 in the anaplastic thyroid cell line KTC2 (Fig. 3C ) decreased miR-19 levels (Fig. 3D) . Next, we analyzed the expression of miR-19 in KTC2 cells treated with the BRAF V600E specific inhibitor PLX4032. Inhibition of BRAF V600E with 1 lM PLX4032 resulted in partial inhibition of miR-19 cluster expression after 24 hours of treatment (Fig. 3E) .
BRAF-activated thyroid cells (BRAF group;
In order to understand further the role of the Notch pathway in regulation of transcription of miR-17-92, we used the PC-Notch1 cell line (17) , which overexpresses the Notch1 intracellular domain (NICD). PC-Notch1 cells exhibited activation of Notch signaling, observed as enhanced luminescence in a Notch1-CBF luciferase reporter assay (Fig. 4A) . Analysis of miR-19 expression in PC-Notch1 cells revealed that increased Notch1 signaling strongly induces miR-19a and miR-19b expression (Fig. 4B) .
BRAF inhibits Smad4 via miR-19 in thyroid cells and impairs the TGFb signaling response
As miR-19a and miR-19b are the key components required for miR-17-92 cluster oncogenicity (24), we searched for predicted targets of these miRNAs that could cooperate with the BRAF oncogene to promote malignancy. Bioinformatic searches using the TargetScan tool revealed Smad4, a component of the TGFb signaling pathway, as a potential target of miR-19. The rat and human Smad4 mRNA 3¢-UTRs contain one predicted binding site for miR-19, which is conserved among vertebrates.
Analysis of protein expression by Western blot revealed that BRAF induction reduced Smad4 levels (Fig. 5A) . Furthermore, high iodine treatment blocked BRAF-induced repression of Smad4 (Fig. 5A) . We also assessed protein levels of the sodium-iodide symporter Nis and observed that high iodine did not block BRAF-induced Nis repression (Fig. 5B) .
To characterize the impact of reduced Smad4 protein levels in BRAF-activated thyroid cells, we evaluated the response of these cells to treatment with recombinant TGFb by flow cytometry. We found that BRAF induction (BRAF group) impaired TGFb-mediated G1-phase arrest, and that treatment with high iodine restored G1 arrest in these cells (Fig. 5C) .
In order to investigate the interaction of miR-19 with the Smad4 mRNA 3¢-UTR, we generated a reporter plasmid containing the predicted binding site for miR-19 downstream of the luciferase gene (pmiRGlo-Smad4-wt; Fig. 6 ). Transient transfection of the pmiRGlo-Smad4-wt construct together with miR-19a/miR-19b mimics in Nthy-ori 3-1 cells resulted in a significant *40% reduction in luciferase activity, which could be abolished by the concomitant transfection of anti-miR-19a/anti-miR-19b (Fig. 6) . Moreover, mutation of the predicted miR-19 binding site (pmiRGloSmad4-mut) abolished the inhibitory effect of miR-19a/miR19b mimics on luciferase activity, as did transfection of the let-7a over pmiRGlo-Smad4-wt plasmid.
Next, we evaluated the effects of anti-miR-19 treatment in the BCPAP PTC cell line. We observed that anti-miR19 treatment reduced endogenous levels of miR-19a and miR19b, and increased levels of the SMAD4 protein (Fig. 7A, B) . Anti-miR-19 treatment induced BCPAP cell death, evident as 
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FUZIWARA AND KIMURA an increase in the number of cells with fragmented DNA (three times higher than untreated control cells; Fig. 7C ). Moreover, concomitant anti-miR-19 and rTGFb treatment slightly increased the G1 cell cycle fraction and reduced the G2/S/M fraction, an effect not observed in cells treated with rTGFb alone (Fig. 7D, E) .
Discussion
Here, we show that the BRAF V600E oncogene stimulates expression of the miR-17-92 cluster and disrupts TGFb signaling. Maintaining thyroid cells in high iodine-containing medium prevents this effect, blocking miR-17-92 induction and restoring TGFb responsiveness.
High iodine exerts a protective effect during BRAF V600E oncogene activation by blocking upregulation of miR-17, miR-18, miR-19a, miR-19b, and miR-20. We have previously reported a protective role for high iodine during oncogenic activation of RET/PTC3 in thyroid follicular cells, by blocking pERK phosphorylation (8) . A recent study indicated that miR-19 is the main oncogenic component of the cluster, as this miRNA alone is sufficient for promotion of c-Mycinduced lymphoma development via repression of apoptosis and activation of the AKT-mTOR pathway (24) . Another study showed that miR-92 is expressed at higher levels in comparison to other miR-17-92 cluster components in colon cancer, serving as the key oncogenic miRNA in this type of cancer through targeting the antiapoptotic gene BIM (25) . In thyroid cancer, selective inhibition of miR-19a or miR-17-5p resulted in strong growth reduction and restored expression of PTEN and RB, respectively, in an ATC cell line (10) . Moreover, our present study indicates the importance of miR-19 in BRAF-mediated thyroid oncogenesis. We observed distinct levels of induction of miR-17-92 components in response to BRAF V600E expression, indicating that intrinsic mechanisms of miRNA processing are associated with unequal expression arising from a single primary transcript. A recent study showed that the primary miR-17-92 transcript is differentially processed, depending on the position of the miRNAs within the tertiary structure of the pri-mi-17-92 polycistron, which generates different expression levels (26) . This observation could explain the differing basal levels of miR-17, miR-18, and miR-19, which are substantially lower than those of miR-20 and miR-92 in rat thyroid follicular cells. Moreover, treatment with iodine alone stimulates punctually miR-20 and miR-92, indicating the existence of a complex and controlled mechanism of primary-miR-17-92 processing or an independent precursor miRNA induction mechanism. Interestingly, a recent study revealed that the presence of the RNA-binding protein, hnRNP1 A1, is important for the processing of miR-18a (27) , pointing to the existence of a finely tuned balance of independent expression of these miRNAs.
One of the known stimulators of miR-17-92 is the protooncogene c-Myc. The human, mouse, and rat miR-17-92 promoter regions contain multiple consensus binding sequences for c-Myc, indicating possible regulation by this transcription factor. O'Donnell et al. showed that c-Myc binds to the promoter region and induces miR-17-92 expression in HeLa cells and that Myc deletion in rat cells reduces miR-17-92 levels, indicating an important influence of c-Myc on transcriptional regulation of the cluster (28) . However, in our study, we observed that BRAF V600E -induced miR-17-92 expression is not associated with enhanced Myc binding in thyroid follicular cells (data not shown), indicating that miR-17-92 upregulation could be associated with a Mycindependent mechanism. Indeed, bioinformatic analyses of the rat miR-17-92 upstream region revealed putative binding sites for Hes1 (induced by Notch signaling) and NFjB transcription factors, in addition to c-Myc, which could influence the transcription of miR-17-92. NFjB (29) and Notch (17) For site binding control, we used pH1-RNA let-7a to overexpress let-7a that does not bind to the Smad4 3¢-UTR. Luminescence (a.u.) was normalized by Renilla luciferase activity contained in the pmiR-Glo plasmid. Data are expressed as mean -SD (n = 3). *p < 0.01 vs. pmiR-Glo Smad4-wt. could ablate TGFb inhibitory signaling and contribute to tumorigenesis. Reduced SMAD4 expression is observed in PTC cell lines, which limits the response to TGFb antiproliferative signaling, as overexpression of SMAD4 blocks cell proliferation and reduces invasion (31) . Here, we show that BRAF V600E -induced expression of miR-19a/miR-19b targets Smad4 and impairs TGFb-induced G1-arrest, which can be reversed by treatment with iodine. Moreover, inhibition of miR-19 in a thyroid cancer cell line increases SMAD4 expression and activates cell cycle arrest in response to TGFb. Interestingly, Smad4 is also controlled by miR-146b (32), which is overexpressed in PTC (33) , and whose expression is driven by the BRAF V600E and RET/PTC oncogenes. These complex interactions of miRNAs targeting the same mRNA indicate an additive effect of miR-19, miR-18, and miR-146b for the ablation of TGFb inhibitory signaling during thyroid oncogenesis.
miR-17-92 is also overexpressed in aggressive lung cancer (11) , and combined expression of miR-17-3p and miR-19b-1 interacts with c-Myc expression to accelerate tumor development in a mouse B-cell lymphoma model (12) . ATC, the most aggressive histotype, exhibits miR-17-92 overexpression, while antisense inhibition of miR-17-92 reduces proliferation and induces apoptosis and cell senescence (10) . Our results show that inhibition of BRAF V600E by the specific inhibitor PLX4032 in the KTC-2 ATC cell line reduces expression of the miR-17-92 cluster and that knockdown of NOTCH1 in cells also inhibits miR-19a/b, indicating ATC cells exhibit BRAF V600E /NOTCH addiction to maintain miR-17-92 upregulation. In this study, we show that high iodine exerts a protective influence over BRAF-activated thyroid cells. Iodine attenuates acute BRAF oncogene induction of miR-19, a newly identified regulator of Smad4, and blocks loss of responsiveness to the TGFb pathway in a mechanism dependent on Notch signaling in thyroid follicular cells (Fig. 8) . Detailed study of the functions of individual miR-17-92 cluster components is important for understanding the overall effect of BRAF V600E -induced miR-17-92 expression in thyroid follicular cells. However, the precise molecular mechanism by which iodine interferes with BRAF oncogene-induced effects and miR-17-92 cluster expression remains to be elucidated.
